Science Explorer Back to mapMap
Discussion
Topic · Molecular Biology

TGF-β signaling in diseases

TGF-β signaling in diseases is a research topic within Molecular Biology. Science Explorer counts 18k research works in it since 1953. 10.0% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the diverse aspects of the Transforming Growth Factor Beta (TGF-ß) signaling pathway, including its role in Smad-dependent and Smad-independent pathways, tumor suppression, cancer progression, bone morphogenetic protein (BMP) signaling, immune response modulation, cell differentiation, metastasis, regulation of epithelial-mesenchymal transition (EMT), and angiogenesis. It also discusses the development and use of TGF-ß inhibitors for potential therapeutic interventions.

  • Smad-dependent pathways
  • Tumor Suppression
  • Cancer Progression
  • BMP signaling
  • Immune Response
  • Cell Differentiation
  • Metastasis
  • Regulation of EMT
  • Angiogenesis
  • TGF-ß Inhibitors
Research works
18k
fractional, since 1953
In the world top 10%
1.8k
per year above
Top-10% rate
10.0%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
-20%
the tick is no change
Largest producer
China
52% of the 10 largest, 2022-now
TGF-β signaling in diseases

Which countries lead TGF-β signaling in diseases research?

By volume, China and the United States publish the most (817 and 341 works in 2022-now).

By volume, 2022-now

  1. 1 China 817 works
  2. 2 United States 341 works
  3. 3 Japan 91 works
  4. 4 Germany 67 works
  5. 5 India 57 works
  6. 6 South Korea 55 works
  7. 7 United Kingdom 49 works
  8. 8 France 37 works
  9. 9 Canada 34 works
  10. 10 Italy 32 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 51.8%United States: 21.6%Japan: 5.7%Germany: 4.2%6 others listed: 16.6%52%largest
China817 · 51.8%United States341 · 21.6%Japan91 · 5.7%Germany67 · 4.2%6 others listed262 · 16.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead TGF-β signaling in diseases research?

By volume in 2022-now, Shanghai Jiao Tong University publishes the most TGF-β signaling in diseases research, followed by Sun Yat-sen University and Chongqing Medical University.

By volume, 2022-now

  1. 1 Shanghai Jiao Tong UniversityChina 21 works
  2. 2 Sun Yat-sen UniversityChina 19 works
  3. 3 Chongqing Medical UniversityChina 16 works
  4. 4 Sichuan UniversityChina 16 works
  5. 5 Harvard UniversityUnited States 15 works
  6. 6 Nanjing Medical UniversityChina 15 works
  7. 7 Zhejiang UniversityChina 15 works
  8. 8 Southern Medical UniversityChina 13 works
  9. 9 Central South UniversityChina 13 works
  10. 10 Peking UniversityChina 13 works

Who are the leading researchers in TGF-β signaling in diseases?

The most-cited researchers publishing on TGF-β signaling in diseases include Eric S. Lander, George Davey Smith and Bert Vogelstein.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 George Davey Smith United Kingdom 435k citations
  3. 3 Bert Vogelstein United States 373k citations
  4. 4 Cyrus Cooper United Kingdom 342k citations
  5. 5 Jun Wang China 340k citations
  6. 6 Matthias Mann Germany 308k citations
  7. 7 Robert A. Weinberg United States 301k citations
  8. 8 Todd R. Golub United States 283k citations
  9. 9 Chris Sander United States 276k citations
  10. 10 Michael Karin United States 276k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in TGF-β signaling in diseases?

The most cited paper in TGF-β signaling in diseases is "Molecular mechanisms of epithelial–mesenchymal transition" (Samy Lamouille, Jian Xu, Rik Derynck, 2014), with 8,337 citations. Next come "TGF-β SIGNAL TRANSDUCTION" (7,585) and "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis" (6,916).

Most cited papers
#PaperReleasedCitations
1 Molecular mechanisms of epithelial–mesenchymal transition Samy Lamouille, Jian Xu, Rik Derynck · Nature Reviews Molecular Cell Biology ReviewOpen access 21 Feb 2014 8,337
2 TGF-β SIGNAL TRANSDUCTION Joan Massagué · Annual Review of Biochemistry Review Jun 1998 7,585
3 Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis Douglas Hanahan, Judah Folkman · Cell Open access Aug 1996 6,916
4 Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus Yigong Shi, Joan Massagué · Cell Open access Jun 2003 5,907
5 Smad-dependent and Smad-independent pathways in TGF-β family signalling Rik Derynck, Ying E. Zhang · Nature 8 Oct 2003 5,416
All 100 most cited papers, with filters and sorting

Where is TGF-β signaling in diseases research done?

The largest centres of TGF-β signaling in diseases research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Wuhan (China).

Largest cities, 2022-now

  1. 1 BeijingChina 69 works
  2. 2 ShanghaiChina 63 works
  3. 3 GuangzhouChina 53 works
  4. 4 WuhanChina 34 works
  5. 5 HangzhouChina 31 works
  6. 6 Xi'anChina 27 works
  7. 7 JinanChina 27 works
  8. 8 ChongqingChina 27 works
  9. 9 NanjingChina 25 works
  10. 10 SeoulSouth Korea 25 works
See TGF-β signaling in diseases on the map

Where is the best place to study TGF-β signaling in diseases?

Among universities, judged by research, Harvard University, Shanghai Jiao Tong University and Sun Yat-sen University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 15.34%fractional works in this field (log) →share of work in the world top 10% →Sun Yat-sen UniversitySichuan UniversityShanghai Jiao Tong U…Harvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 68.013.6%2.8×16 -30.0%
2Shanghai Jiao Tong UniversityChina 67.517.7%4.3×21 -22.5%
3Sun Yat-sen UniversityChina 64.819.3%5.5×19 -20.9%
4Sichuan UniversityChina 58.817.8%4.1×16 -27.7%
5Harbin Medical UniversityChina 54.115.6%20.1×12 +51.9%
6Zhejiang UniversityChina 51.516.0%3.3×15 -9.7%
7Huazhong University of Science and TechnologyChina 45.218.6%4.0×12 -31.1%
8Peking UniversityChina 44.814.0%3.6×13 +3.2%
9Chongqing Medical UniversityChina 42.36.7%16.8×16 +2.0%
10Wuhan UniversityChina 40.314.1%5.2×13 -20.6%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in TGF-β signaling in diseases, country by country

Is TGF-β signaling in diseases research growing?

Output in 2022-2025 was 20% lower than in 2018-2021, peaking in 2013.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is TGF-β signaling in diseases as a percentage of every work published that year, 0.0065% in 2024.

still counting0.020%0.040%TGF-β signaling in diseases0.0078% in 202519801990200020102020

Fractional works of TGF-β signaling in diseases over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%TGF-β signaling in diseases10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about TGF-β signaling in diseases. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.